Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

astellas pharma europe b.v. - josamycinum - comprimate dispersabile - 1000 mg

Unjoni Ewropea - Rumen - EMA (European Medicines Agency)

laboratorios lesvi s.l. - fumarat de dimetil - scleroză multiplă, scleroză multiplă recurent-remisivă - imunosupresoare - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

nobel ilac sanayii ve ticaret a.Ş. - roxithromycinum - comprimate filmate - 150 mg

Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

sc balkan pharmaceuticals srl - cefazolinum - pulbere pentru soluţie injectabilă/perfuzabilă - 1 g

Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

medochemie ltd - cefazolinum - pulbere pentru soluţie injectabilă/perfuzabilă - 1 g

Unjoni Ewropea - Rumen - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrita, reumatoida - imunosupresoare - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

farmex company s.r.l. sc - oxacillinum - capsule - 500 mg

Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

nobel ilac sanayii ve ticaret a.Ş. - roxithromycinum - comprimate filmate - 150 mg

Maldova - Rumen - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

astellas pharma europe b.v. - comprimate orodispersabile - 1000 mg

Unjoni Ewropea - Rumen - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, sistemic - imunosupresoare - benlysta este indicat ca terapie adjuvantă la pacienții în vârstă de 5 ani și mai în vârstă cu active, autoanticorpi pozitivi lupus eritematos sistemic (les) cu un grad înalt de activitate a bolii (e. , pozitiv anti adndc și joasă de completare) în ciuda terapiei standard. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.